Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Internal R&D vs. CROs: AstraZeneca, Novartis Tout Advantages Of Staying In-House

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis reports savings of $100 mil. by decreasing its use of contract research organizations. AstraZeneca sees improved R&D productivity by relying less on CROs and by conducting clinical trials outside the U.S.

You may also be interested in...



GSK Predicts Outsourcing R&D To “Low-Cost” Countries Could Save $200 Mil.

Each outsourced clinical trial patient could save GSK up to $15,000, CEO Garnier estimates. The company is exploring a number of ways to control R&D costs, the exec says, citing electronic data capture as another potential option.

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.

Topics

UsernamePublicRestriction

Register

PS058568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel